Tolbutamide is a first-generation potassium channel blocker, sulfonylurea oral hypoglycemic medication. This drug may be used in the management of type 2 diabetes if diet alone is not effective. Tolbutamide stimulates the secretion of insulin by the pancr + some more technical info. It exerts its effect by binding the sulfonylurea receptor 1 subunit on pancreatic beta cell ATP-sensitive potassium channels, causing channel closure, membrane depolarization, calcium influx and insulin granule exocytosis. After oral dosing tolbutamide is rapidly absorbed with peak plasma concentrations typically within 1 to 3 hours, is highly protein bound, and has an elimination half-life in the range of approximately 4 to 6 hours in healthy adults. Metabolism is primarily hepatic via CYP2C9 mediated oxidation to inactive metabolites that are renally excreted. Clinically relevant considerations include risk of hypoglycemia, interactions with CYP2C9 inhibitors or inducers, and dose adjustment or monitoring in significant hepatic or renal impairment.
Parent: Gliclazide/ Tolbutamide / Tolazoline
Parent: Tolbutamide
Typical pharmaceutical quality specifications for tolbutamide active pharmaceutical ingredient include an assay specification commonly around 98.0 to 102.0 percent and limits for related substances that reflect ICH principles and manufacturer stability data. Example specification limits used in practice are individual impurity not greater than 0.2 percent and total impurities not exceeding 1.0 percent, with any identified genotoxic impurities controlled to much lower thresholds in line with ICH M7 guidance (for example 0.05 percent or per calculated permissible intake). Common related compounds and degradation products monitored during release and stability testing include p-toluenesulfonamide related residues, minor hydroxylated or carboxylated tolbutamide metabolites, desalkylated derivatives and other process-related impurities; these are typically detected and quantified by validated HPLC-UV methods with MS confirmation when identification is required.
Tolbutamide is used to lower blood glucose in patients with type 2 diabetes when diet, exercise and lifestyle measures alone are insufficient. It increases insulin secretion from pancreatic beta cells.
Yes, Tolbutamide is a first-generation sulfonylurea that acts on ATP-sensitive potassium channels of pancreatic beta cells.
Availability depends on country and manufacturer. Tolbutamide is no longer widely prescribed in many markets and has been superseded by newer oral agents, though it may still be available in some regions or as a legacy generic formulation.
Use of tolbutamide declined after historical safety signals, including concerns about cardiovascular outcomes reported in early trials, and because newer sulfonylureas and other classes of glucose-lowering drugs with improved safety and pharmacokinetic profiles became available. Manufacturers and prescribers shifted to these alternatives, leading to limited availability in many markets.
